Page 156 - MEMORIA ANUAL 2021
P. 156

   MEMORIA ANUAL 2021 SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
GELTAMO
FUNDACIÓN ESPAÑOLA DE HEMATOLOGÍA Y HEMOTERAPIA
  Cancer Med. 2021 Feb;10(4):1314-26. doi: 10.1002/cam4.3730.
Sancho JM, Fernández-Álvarez R, Gual-Capllonch F, González-García E, Grande C, Gutié- rrez N, Peñarrubia MJ, Batlle-López A, González-Barca E, Guinea JM, Gimeno E, Peñalver FJ, Fuertes M, Bastos M, Hernández-Rivas JÁ, Moraleda JM, García O, Sorigué M, Martín A .
• Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neopla- sias: A Registry Study from Spanish GETH/GELTAMO Centers.
Transplant Cell Ther. 2021 Jun;27(6):493.e1-493.e8. doi: 10.1016/j.jtct.2021.03.014. Novelli S, Bento L, García I, Prieto L, López L, Gutiérrez G, Hernani R, Pérez A, Esquirol A, Solano C, Bastos M, Dorado N, Rodríguez N, Rodríguez G, Piñana JL, Montoro J, Herrera P, Luna A, Parody R, Martín C, García E, López O, Heras I, Zanabili J, Moraleda JM, Yáñez L, Gutiérrez A, Zudaire T, Córdoba R, Varela R, Ferra C, Martínez J, Martínez C, González- Barca E, Martino R, Caballero D; GELTAMO and GETH .
• Allogeneic stem cell transplantation as a curative option in relapse/refractory dif- fuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study.
Bone Marrow Transplant. 2021 Aug;56(8):1919-28. doi: 10.1038/s41409-021-01264-3. Bento L, Gutiérrez A, Novelli S, Montoro J, Piñana JL, López-Corral L, Cabrero M, Martín- Sancho A, Gutiérrez-García G, Ortiz-Moscovich M, Bastos-Oreiro M, Dorado N, Pérez A, Hernani R, Ferrà C, Parody R, García-Cadenas I, Herrera P, Rodríguez G, Rodríguez N, Martín C, Yáñez L, Zanabili J, Varela MR, López-Godino O, Heras I, Español I, Martínez C, Pérez-Simón JA, Solano C, Sureda A, Sierra J, Sampol A, Caballero D; Grupo Español de Trasplante Hematopoyético (GETH) y Grupo Español de Linfoma y Trasplante Autólogo (GELTAMO) .
• Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma.
Cancer Med. 2021 May;10(10):3214-23. doi: 10.1002/cam4.3881.
Iacoboni G, Villacampa G, Martínez-Cibrián N, Bailén R, López Corral L, Sánchez JM, Gue- rreiro M, Caballero AC, Mussetti A, Sancho JM, Hernani R, Abrisqueta P, Solano C, Sureda A, Briones J, Martín García-Sancho A, Kwon M, Reguera-Ortega JL, Barba P; GETH, GEL- TAMO Spanish Groups .
• A randomized phase II study comparing consolidation with a single dose of Y ibritu- momab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results. Leuk Lymphoma. 2021 Aug 30:1-8. doi: 10.1080/10428194.2021.1971216. Epub ahead of print. López-Guillermo A, Canales MÁ, Dlouhy I, Mercadal S, Briones J, Martín García-Sancho A, Sancho JM, Moraleda JM, Terol MJ, Salar A, Palomera L, Gardella S, Jarque I, Ferrer S,
 156
 



















































































   154   155   156   157   158